Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
The deal expands the pharmaceutical company’s portfolio of cancer drugs. Source link
BMY
Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion
Bristol-Myers Squibb Co. said it will acquire biotechnology company Turning Point Therapeutics Inc. TPTX 116.76% for $4.1 billion, an effort...
